Restart Life Sciences Corp.
NMLSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $4 | $5 |
| Gross Profit | $0 | $25 | -$4 | -$5 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $71 | $115 | $860 |
| G&A Expenses | $402 | $858 | $1,818 | $2,069 |
| SG&A Expenses | $402 | $1,131 | $1,818 | $2,069 |
| Sales & Mktg Exp. | $0 | $273 | $0 | $0 |
| Other Operating Expenses | $221 | $0 | $4 | -$136 |
| Operating Expenses | $624 | $1,202 | $1,937 | $2,793 |
| Operating Income | -$624 | -$1,202 | -$1,842 | -$2,798 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $849 | -$22 | -$624 | $114 |
| Pre-Tax Income | $225 | -$1,224 | -$2,466 | -$2,685 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $225 | -$1,224 | -$2,466 | -$2,685 |
| % Margin | – | – | – | – |
| EPS | 0.015 | -0.083 | -0.18 | -0.24 |
| % Growth | 117.7% | 53.8% | 25% | – |
| EPS Diluted | 0.014 | -0.083 | -0.18 | -0.24 |
| Weighted Avg Shares Out | 15,286 | 14,717 | 13,656 | 11,110 |
| Weighted Avg Shares Out Dil | 16,114 | 14,717 | 13,656 | 11,110 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $230 | $98 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $3 | $4 | $5 |
| EBITDA | -$656 | -$1,202 | -$1,842 | -$2,798 |
| % Margin | – | – | – | – |